Lowering of brain endothelial cell barrier function by exposure to 4'-iodo-α-pyrrolidinononanophenone.

[1]  A. Ikari,et al.  Apoptotic mechanism in human brain microvascular endothelial cells triggered by 4'-iodo-α-pyrrolidinononanophenone: contribution of decrease in antioxidant properties , 2021, Toxicology Letters.

[2]  Jingjing Zhang,et al.  Claudin-5 Affects Endothelial Autophagy in Response to Early Hypoxia , 2021, Frontiers in Physiology.

[3]  A. Ikari,et al.  9,10-Phenanthrenequinone provokes dysfunction of brain endothelial barrier through down-regulating expression of claudin-5. , 2021, Toxicology.

[4]  T. Ulutin,et al.  Anti-cancer effect of metformin on the metastasis and invasion of primary breast cancer cells through mediating NF-kB activity. , 2021, Acta histochemica.

[5]  A. Andrews,et al.  The psychoactive drug of abuse mephedrone differentially disrupts blood-brain barrier properties , 2021, Journal of neuroinflammation.

[6]  Y. Okada,et al.  Claudin-5: A Pharmacological Target to Modify the Permeability of the Blood-Brain Barrier. , 2021, Biological & pharmaceutical bulletin.

[7]  M. Gunnell,et al.  Pharmacokinetics of α-Pyrrolidinovalerophenone in Male Rats with and without Vaccination with an α-Pyrrolidinovalerophenone Vaccine. , 2021, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[8]  P. Adamowicz.  Blood concentrations of synthetic cathinones , 2020, Clinical toxicology.

[9]  A. Ikari,et al.  4′-Fluoropyrrolidinononanophenone elicits neuronal cell apoptosis through elevating production of reactive oxygen and nitrogen species , 2020, Forensic Toxicology.

[10]  Qiu-ying Jia,et al.  Inflammation, apoptosis and autophagy as critical players in vascular dementia. , 2020, European review for medical and pharmacological sciences.

[11]  T. Davis,et al.  Structure, Function, and Regulation of the Blood-Brain Barrier Tight Junction in Central Nervous System Disorders , 2020, Frontiers in Physiology.

[12]  Yunman Li,et al.  Research progress of mechanisms for tight junction damage on blood–brain barrier inflammation , 2020, Archives of physiology and biochemistry.

[13]  K. Miyazono,et al.  TNF‐α enhances TGF‐β‐induced endothelial‐to‐mesenchymal transition via TGF‐β signal augmentation , 2020, Cancer science.

[14]  S. Vishnupriya,et al.  Oxidative stress responsive transcription factors in cellular signalling transduction mechanisms. , 2020, Cellular signalling.

[15]  M. Campbell,et al.  Tight junction modulation at the blood-brain barrier: Current and future perspectives. , 2020, Biochimica et biophysica acta. Biomembranes.

[16]  K. Parker,et al.  Human brain microvascular endothelial cell pairs model tissue-level blood-brain barrier function. , 2020, Integrative biology : quantitative biosciences from nano to macro.

[17]  Q. Jiao,et al.  FoxO1 regulates TLR4/MyD88/MD2‐NF‐κB inflammatory signalling in mucosal barrier injury of inflammatory bowel disease , 2020, Journal of cellular and molecular medicine.

[18]  F. Carvalho,et al.  Structure-cytotoxicity relationship profile of 13 synthetic cathinones in differentiated human SH-SY5Y neuronal cells. , 2019, Neurotoxicology.

[19]  T. Poulos,et al.  Optimization of Blood-Brain Barrier Permeability with Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors Having a 2-Aminopyridine Scaffold. , 2019, Journal of medicinal chemistry.

[20]  A. Sporbert,et al.  Tight junction proteins at the blood–brain barrier: far more than claudin-5 , 2019, Cellular and Molecular Life Sciences.

[21]  C. Greene,et al.  Claudin-5: gatekeeper of neurological function , 2019, Fluids and Barriers of the CNS.

[22]  Jingjing Zhang,et al.  Autophagy Protects the Blood-Brain Barrier Through Regulating the Dynamic of Claudin-5 in Short-Term Starvation , 2019, Front. Physiol..

[23]  Marta Kedzierska,et al.  Cytotoxicity of α-Pyrrolidinophenones: an Impact of α-Aliphatic Side-chain Length and Changes in the Plasma Membrane Fluidity , 2018, Neurotoxicity Research.

[24]  J. P. Issa,et al.  MMPs are Involved in Osteoporosis and are Correlated with Cardiovascular Diseases. , 2018, Current pharmaceutical design.

[25]  Berislav V. Zlokovic,et al.  Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders , 2018, Nature Reviews Neurology.

[26]  N. Williams,et al.  Dose-dependent expression of claudin-5 is a modifying factor in schizophrenia , 2017, Molecular Psychiatry.

[27]  M. Sajewicz,et al.  The newest cathinone derivatives as designer drugs: an analytical and toxicological review , 2017, Forensic Toxicology.

[28]  O. El-Kabbani,et al.  α-Pyrrolidinononanophenone provokes apoptosis of neuronal cells through alterations in antioxidant properties. , 2017, Toxicology.

[29]  M. Chopp,et al.  Blood–Brain Barrier Disruption, Vascular Impairment, and Ischemia/Reperfusion Damage in Diabetic Stroke , 2017, Journal of the American Heart Association.

[30]  M. Colado,et al.  3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) produces edema due to BBB disruption induced by MMP-9 activation in rat hippocampus , 2017, Neuropharmacology.

[31]  O. El-Kabbani,et al.  Structure-activity relationship for toxicity of α-pyrrolidinophenones in human aortic endothelial cells , 2017, Forensic Toxicology.

[32]  Gregory G. Grecco,et al.  Cooling down the bath salts: Carvedilol attenuation of methylone and mephedrone mediated hyperthermia. , 2016, Toxicology letters.

[33]  C. Lançon,et al.  The effects and risks associated to mephedrone and methylone in humans: A review of the preliminary evidences , 2016, Brain Research Bulletin.

[34]  M. Paule,et al.  3,4-methylenedioxypyrovalerone (MDPV) Induces Cytotoxic Effects on Human Dopaminergic SH-SY5Y Cells , 2016 .

[35]  B. Yamamoto,et al.  Peripheral ammonia and blood brain barrier structure and function after methamphetamine , 2016, Neuropharmacology.

[36]  A. Helander,et al.  Toxicity evaluation of α-pyrrolidinovalerophenone (α-PVP): results from intoxication cases within the STRIDA project , 2016, Clinical toxicology.

[37]  T. Wright,et al.  Twenty-One Cases Involving Alpha-Pyrrolidinovalerophenone (α-PVP). , 2016, Journal of analytical toxicology.

[38]  K. Kudo,et al.  A fatal case of poisoning related to new cathinone designer drugs, 4-methoxy PV8, PV9, and 4-methoxy PV9, and a dissociative agent, diphenidine. , 2015, Legal medicine.

[39]  P. Urbánek,et al.  Redox regulation of FoxO transcription factors , 2015, Redox biology.

[40]  I. Papoutsis,et al.  α-PVP (“flakka”): a new synthetic cathinone invades the drug arena , 2015, Forensic Toxicology.

[41]  D. Graves,et al.  FOXO Transcription Factors: Their Clinical Significance and Regulation , 2014, BioMed research international.

[42]  O. Suzuki,et al.  Postmortem distribution of PV9, a new cathinone derivative, in human solid tissues in a fatal poisoning case , 2014, Forensic Toxicology.

[43]  J. Zawilska,et al.  Designer cathinones--an emerging class of novel recreational drugs. , 2013, Forensic science international.

[44]  Heather M. Antonides,et al.  Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results. , 2013, Journal of analytical toxicology.

[45]  A. Ishii,et al.  Recently abused synthetic cathinones, α-pyrrolidinophenone derivatives: a review of their pharmacology, acute toxicity, and metabolism , 2013, Forensic Toxicology.

[46]  G. Jickling,et al.  New approach to identify ischemic stroke patients at risk to develop hemorrhagic transformation. , 2012, Maedica.

[47]  Xin Wei,et al.  Tight Junction in Blood‐Brain Barrier: An Overview of Structure, Regulation, and Regulator Substances , 2012, CNS neuroscience & therapeutics.

[48]  E. Lo,et al.  Neurovascular matrix metalloproteinases and the blood-brain barrier. , 2012, Current pharmaceutical design.

[49]  M. Merhav,et al.  The ubiquitin–proteasome pathway regulates claudin 5 degradation , 2012, Journal of cellular biochemistry.

[50]  Bernhard Hennig,et al.  Oxidative stress and blood-brain barrier dysfunction under particular consideration of matrix metalloproteinases. , 2011, Antioxidants & redox signaling.

[51]  J. Kelly,et al.  Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. , 2011, Drug testing and analysis.

[52]  Henry A Spiller,et al.  Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States , 2011, Clinical toxicology.

[53]  Michael M. Wang,et al.  Caveolae-mediated Internalization of Occludin and Claudin-5 during CCL2-induced Tight Junction Remodeling in Brain Endothelial Cells* , 2009, The Journal of Biological Chemistry.

[54]  Maxime Culot,et al.  Modelling of the blood–brain barrier in drug discovery and development , 2007, Nature Reviews Drug Discovery.

[55]  S. Matalon,et al.  Upregulation of immunoproteasomes by nitric oxide: potential antioxidative mechanism in endothelial cells. , 2006, Free radical biology & medicine.

[56]  N. Motoyama,et al.  FOXO transcription factors in cell-cycle regulation and the response to oxidative stress. , 2005, Antioxidants & redox signaling.

[57]  A. Haas,et al.  Nitric oxide inhibits H2O2-induced transferrin receptor-dependent apoptosis in endothelial cells: Role of ubiquitin-proteasome pathway , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[58]  S. Tsukita,et al.  Size-selective loosening of the blood-brain barrier in claudin-5–deficient mice , 2003, The Journal of cell biology.

[59]  S. Usui,et al.  Growth suppressing activity for endothelial cells induced from macrophages by carboxymethylated curdlan. , 1997, Bioscience, biotechnology, and biochemistry.

[60]  S. Mohan,et al.  Differential activation of NF-kappa B in human aortic endothelial cells conditioned to specific flow environments. , 1997, The American journal of physiology.